Humana Files 8-K on Operations & Financial Condition

TL;DR

**Humana just dropped an 8-K on its financials, get ready for potential stock movement.**

AI Summary

Humana Inc. filed an 8-K on January 18, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD Disclosure. This filing indicates that Humana is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For stockholders, this matters because it provides timely information that could influence the stock's price and their investment decisions.

Why It Matters

This filing signals that Humana is updating the market on its financial performance, which can directly impact investor confidence and stock valuation. Investors should pay close attention to the details of the financial condition and results of operations.

Risk Assessment

Risk Level: medium — While an 8-K itself isn't inherently risky, the 'Results of Operations and Financial Condition' item suggests important financial updates that could contain positive or negative news, creating uncertainty.

Analyst Insight

A smart investor would await the full details of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' to understand the specific financial updates and their implications before making any investment decisions.

Key Players & Entities

• Humana Inc. (company) — the registrant filing the 8-K
• January 18, 2024 (date) — date of earliest event reported and filing date
• 500 West Main Street, Louisville, KY 40202 (address) — principal executive offices of Humana Inc.
• 0000049071 (number) — Central Index Key (CIK) for Humana Inc.
• 1-5975 (number) — Commission File Number for Humana Inc.

FAQ

Key Financial Figures

• $20.00 — cts to report GAAP EPS of approximately $20.00 in diluted earnings per common share ("
• $26.09 — common share ("EPS"), or approximately $26.09 in Adjusted earnings per common share (

Filing Documents

• hum-20240118.htm (8-K) — 56KB
• 0000049071-24-000005.txt ( ) — 183KB
• hum-20240118.xsd (EX-101.SCH) — 2KB
• hum-20240118_lab.xml (EX-101.LAB) — 24KB
• hum-20240118_pre.xml (EX-101.PRE) — 12KB
• hum-20240118_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. 2024 Individual Medicare Advantage Enrollment Based on the results of the annual election period (AEP), Humana Inc. (the "Company") now expects individual Medicare Advantage (MA) growth of approximately 100,000 members for the year ending December 31, 2024, representing 1.8 percent growth over its membership as of December 31, 2023 of approximately 5.4 million members, compared to its previous commentary of at or slightly above industry average growth'. The Company's membership growth outlook for 2024 is impacted by its balanced approach to pricing which resulted in a lower share of overall industry growth. While the Company's overall AEP sales volume was in line with expectations, a higher proportion was driven by plan change activity by existing members, resulting in lower new member sales than expected. Despite the higher plan change activity, the Company experienced slightly higher attrition during the AEP than expected. Actual AEP growth for the Company is approximately 120,000 members, which is expected to decline slightly by year end due to the more limited sales opportunity post AEP and the expectation that the Company will see slightly higher attrition within its Dual Special Needs Plan (D-SNP) offerings over the next several months as members lose dual eligible status from the on-going Medicaid redetermination process. The Company continues to believe it took a prudent approach to 2024 pricing considering the current regulatory changes and evolving utilization environment. In addition, the Company believes it remains well positioned to compete as an industry leader in the attractive Medicare Advantage market going forward with its differentiated capabilities, including highly diversified and patient centered value-based care arrangements, exceptional quality as demonstrated by its industry leading Stars scores, best in class consumer experience rankings, and continued growth and integration of its CenterWell capabil

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. HUMANA INC. BY: /s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer) Dated: January 18, 2024

View Full Filing

View this 8-K filing on SEC EDGAR